These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Pan Y; Shu JL; Gu HF; Zhou DC; Liu XL; Qiao QY; Fu SK; Gao FH; Jin HM Mol Cell Endocrinol; 2013 Mar; 367(1-2):116-23. PubMed ID: 23313788 [TBL] [Abstract][Full Text] [Related]
8. Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Stone NJ; Saxon D Am J Cardiol; 2005 Aug; 96(4A):15E-21E. PubMed ID: 16098838 [TBL] [Abstract][Full Text] [Related]
9. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Carmina E Front Horm Res; 2013; 40():40-50. PubMed ID: 24002404 [TBL] [Abstract][Full Text] [Related]
10. Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. Hansen E; Hajri T; Abumrad NN Surgery; 2006 Jun; 139(6):711-6. PubMed ID: 16782424 [No Abstract] [Full Text] [Related]
11. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Lo J; Bernstein LE; Canavan B; Torriani M; Jackson MB; Ahima RS; Grinspoon SK Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E102-9. PubMed ID: 17374698 [TBL] [Abstract][Full Text] [Related]
12. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284 [TBL] [Abstract][Full Text] [Related]
13. Dietary and lifestyle interventions in the management of the metabolic syndrome: present status and future perspective. Minehira K; Tappy L Eur J Clin Nutr; 2002 Dec; 56(12):7 p following 1262. PubMed ID: 12494312 [TBL] [Abstract][Full Text] [Related]
14. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Hajer GR; van Haeften TW; Visseren FL Eur Heart J; 2008 Dec; 29(24):2959-71. PubMed ID: 18775919 [TBL] [Abstract][Full Text] [Related]
16. The progression of cardiovascular risk to cardiovascular disease. Rosin BL Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392 [TBL] [Abstract][Full Text] [Related]
17. Adipocytokines and metabolic syndrome. Matsuzawa Y Semin Vasc Med; 2005 Feb; 5(1):34-9. PubMed ID: 15968578 [TBL] [Abstract][Full Text] [Related]
18. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Nourbakhsh M; Nourbakhsh M; Gholinejad Z; Razzaghy-Azar M Scand J Clin Lab Invest; 2015 Apr; 75(2):183-8. PubMed ID: 25723377 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of the metabolic syndrome with lifestyle intervention: where do we start? Sullivan VK J Am Diet Assoc; 2006 May; 106(5):668-71. PubMed ID: 16647323 [No Abstract] [Full Text] [Related] [Next] [New Search]